과제정보
This study was supported by a grant from the Hanwha Chemical Corp. The extremely small-sized iron-based nanoparticles were supplied from Hanwha Chemical Corp. The assistance of Bong-sik Jeon, PhD, Eung-gyu Kim, PhD, and Wan-Jae Myeong, PhD in some of the experiments is gratefully acknowledged.
참고문헌
- Gozzi M, Amorico MG, Colopi S, Favali M, Gallo E, Torricelli P, et al. Peripheral arterial occlusive disease: role of MR angiography. Radiol Med 2006;111:225-237 https://doi.org/10.1007/s11547-006-0023-4
- Lim RP, Shapiro M, Wang EY, Law M, Babb JS, Rueff LE, et al. 3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA. AJNR Am J Neuroradiol 2008;29:1847-1854 https://doi.org/10.3174/ajnr.A1252
- Nael K, Fenchel M, Krishnam M, Finn JP, Laub G, Ruehm SG. 3.0 tesla high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) of the pulmonary circulation: initial experience with a 32-channel phased array coil using a high relaxivity contrast agent. Invest Radiol 2007;42:392-398 https://doi.org/10.1097/01.rli.0000261937.77365.6a
- Prince MR. Gadolinium-enhanced MR aortography. Radiology 1994;191:155-164 https://doi.org/10.1148/radiology.191.1.8134563
- Yucel EK. MR angiography for evaluation of abdominal aortic aneurysm: has the time come? Radiology 1994;192:321-323 https://doi.org/10.1148/radiology.192.2.8029387
- Government of Canada. Gadolinium-containing contrast agents - Update on nephrogenic systemic fibrosis/nephrogenic fibrosing eermopathy (NSF/NFD) - Notice to hospitals. Healthycanadians.gc.ca Web site. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/36711a-eng.php. Accessed August 15, 2018
- U.S. Food and Drug Administration. FDA Drug Safety Communication: new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Fda.gov Web site. https://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed August 15, 2018
- European Medicines Agency. Gadolinium-containing contrast agents. Ema.europa.eu Web site. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_000182.jsp. Accessed August 20, 2018
- Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Revisiting the risks of MRI with gadolinium based contrast agents-review of literature and guidelines. Insights Imaging 2015;6:553-558 https://doi.org/10.1007/s13244-015-0420-2
- Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260:105-111 https://doi.org/10.1148/radiol.11102340
- Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Radiology 2009;253:689-696 https://doi.org/10.1148/radiol.2533090649
- Roch A, Muller RN. Theory of proton relaxation induced by superparamagnetic particles. J Chem Phys 1999;110:5403-5411 https://doi.org/10.1063/1.478435
- Antell H, Numminen J, Abo-Ramadan U, Niemela MR, Hernesniemi JA, Kangasniemi M. Optimization of high-resolution USPIO magnetic resonance imaging at 4.7 T using novel phantom with minimal structural interference. J Magn Reson Imaging 2010;32:1184-1196 https://doi.org/10.1002/jmri.22181
- Ling D, Park W, Park YI, Lee N, Li F, Song C, et al. Multiple-interaction ligands inspired by mussel adhesive protein: synthesis of highly stable and biocompatible nanoparticles. Angew Chem Int Ed Engl 2011;50:11360-11365 https://doi.org/10.1002/anie.201101521
- Hifumi H, Yamaoka S, Tanimoto A, Citterio D, Suzuki K. Gadolinium-based hybrid nanoparticles as a positive MR contrast agent. J Am Chem Soc 2006;128:15090-15091 https://doi.org/10.1021/ja066442d
- Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl 2008;47:5122-5135 https://doi.org/10.1002/anie.200701674
- Kim BH, Lee N, Kim H, An K, Park YI, Choi Y, et al. Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc 2011;133:12624-12631 https://doi.org/10.1021/ja203340u
- Hagberg GE, Scheffler K. Effect of r1 and r2 relaxivity of gadolinium-based contrast agents on the T1-weighted MR signal at increasing magnetic field strengths. Contrast Media Mol Imaging 2013;8:456-465 https://doi.org/10.1002/cmmi.1565
- Na HB, Lee IS, Seo H, Park YI, Lee JH, Kim SW, et al. Versatile PEG-derivatized phosphine oxide ligands for water-dispersible metal oxide nanocrystals. Chem Commun (Camb) 2007;48:5167-5169 https://doi.org/10.1039/b712721a
- Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991;9:275-283 https://doi.org/10.1016/0730-725X(91)90412-F
- Park EA, Lee W, So YH, Lee YS, Jeon BS, Choi KS, et al. Extremely small pseudoparamagnetic iron oxide nanoparticle as a novel blood pool T1 magnetic resonance contrast agent for 3 T whole-heart coronary angiography in canines: comparison with gadoterate meglumine. Invest Radiol 2017;52:128-133 https://doi.org/10.1097/RLI.0000000000000321
- Malikova H, Holesta M. Gadolinium contrast agents - are they really safe? J Vasc Access 2017;18:1-7 https://doi.org/10.5301/jva.5000713
- Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, et al. Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian association of radiologists. Can Assoc Radiol J 2018;69:136-150 https://doi.org/10.1016/j.carj.2017.11.002
- Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015;276:741-747 https://doi.org/10.1148/radiol.2015142423
- Janus N, Launay-Vacher V, Karie S, Clement O, Ledneva E, Frances C, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2010;73:357-359 https://doi.org/10.1016/j.ejrad.2008.11.021
- Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, et al. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 2013;23:1250-1259 https://doi.org/10.1007/s00330-012-2705-x
- Amet S, Launay-Vacher V, Clement O, Frances C, Tricotel A, Stengel B, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogenique Systemique study. Invest Radiol 2014;49:109-115 https://doi.org/10.1097/RLI.0000000000000000
- Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging 2017;45:988-997 https://doi.org/10.1002/jmri.25486
- Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Updated clinical practice guideline on use of gadolinium-based contrast agents in kidney disease issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2019;70:226-232 https://doi.org/10.1016/j.carj.2019.04.001
- Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis. Radiology 2019;292:376-386 https://doi.org/10.1148/radiol.2019182916
- Liu G, Gao J, Ai H, Chen X. Applications and potential toxicity of magnetic iron oxide nanoparticles. Small 2013;9:1533-1545 https://doi.org/10.1002/smll.201201531
- Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest Radiol 2012;47:717-724 https://doi.org/10.1097/RLI.0b013e31826dc151
- Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M. Toxicity of nanomaterials. Chem Soc Rev 2012;41:2323-2343 https://doi.org/10.1039/C1CS15188F